Corbus Pharmaceuticals to Present Anti-Inflammatory Drug for CF at VirtualInvestorConferences.com

Corbus Pharmaceuticals has been invited to present during this Thursday’s VirtualInvestorConferences.com on its lead pipeline product Resunab™, indicated for the treatment of serious inflammatory and fibrotic diseases, namely cystic fibrosis and diffuse scleroderma. Representing the company during the upcoming online, live event is CEO Yuval Cohen, Ph.D., scheduled on Thursday, December 4, 2014 at 11:30 a.m. EST. Resunab is an oral formulation of a synthetic CB2 agonist which binds to receptors on immune cells to trigger the production of anti-inflammatory substances such as PGJ2 and Lipoxin A4, which contribute to an innate “off switch” for inflammatory processes. Dr. Cohen’s presentation on Resunab covers its progress updates and clinical development milestones.

Cystic fibrosis is a chronic, life-threatening disorder that affects the lungs and the digestive tract, causing excessive, thick mucus to build up and predispose the patient to serious lung infections, and malnutrition. Diffuse scleroderma is a chronic connective tissue disease that may manifest mildly, but can likely affect internal organs and potentially lead to life-threatening organ failure. There are no known cures for either of the two fibrotic diseases, therefore treatment is focused on symptom management via anti-inflammatory agents.

[adrotate group=”1″]

The VirtualInvestorConferences.com online event allows real-time interaction between physically- and virtually-present participants, and invited speakers. Since its founding in 2010 by BetterInvesting (NAIC) and PR Newswire, it has broadcasted monthly investor conferences that conveniently fosters networking between emerging companies and potential investors. Its unique design and platform replicates an actual location-based conference, and leverages PR Newswire’s influential communications network, with BetterInvesting’s retail investor audience.

Dr. Cohen’s presentation will be broadcasted exlusively through VirtualInvestorConferences.com, and subsequently stored in an on-demand archive for 90 days. Corbus Pharmaceuticals will also make a link to the virtual conference available on its corporate website www.corbuspharma.com, under the Investors section, in News and Events on the IR Calendar.

While reducing inflammation is important in cystic fibrosis, addressing harmful lung infections, such as those caused by Pseudomonas aeruginosa, is crucial to avoid life-threatening complications of the disease. According to a study conducted at the University of Liverpool’s Institute of Infection and Global Health, UK, published in Nature Communications, and led by the group of the Professors Aras Kadioglu and Craig Winstanley, the nasopharynx may be housing growths of this bacteria and could be the source of recurrent respiratory infections in CF patients.